文献速递创伤骨科

股骨骨折手术治疗后手术部位多模式药物注射的疗效:随机对照试验

Efficacy of Surgical-Site, Multimodal Drug Injection Following Operative Management of Femoral Fractures: A Randomized Controlled Trial.
PubMed 文献 · J Bone Joint Surg Am · 2017-01-01

该随机对照试验纳入102例接受手术(钢板固定、髓内装置或关节置换)的股骨骨折患者,比较术中手术部位注射罗哌卡因、肾上腺素和吗啡混合液与不注射的镇痛效果。注射组在恢复室及术后4、8、12小时视觉模拟量表评分显著低于对照组,术后8小时内麻醉药品消耗量显著减少,未观察到局麻药相关心脏或中枢神经系统毒性。

要点

  • 股骨骨折手术后手术部位注射多模式镇痛混合液可显著降低术后早期疼痛评分。
  • 注射组术后8小时内麻醉药品消耗量显著低于对照组。
  • 未观察到局麻药浸润继发的心脏或中枢神经系统毒性。

核心结论

  • 手术部位注射多模式镇痛混合液可改善术后第一天疼痛控制并减少麻醉药品使用,在因股骨骨折接受手术的多样化骨科创伤人群中未观察到归因于局部注射的不良反应。

研究设计与样本

  • 前瞻性随机对照试验,纳入102例因各种类型股骨骨折接受手术干预(钢板固定、髓内装置或关节置换)的患者,随机分为接受含罗哌卡因、肾上腺素和吗啡的术中手术部位浅层和深层组织注射组或不注射组。

主要发现

  • 注射组在恢复室及术后4、8、12小时视觉模拟量表评分显著低于对照组(p < 0.05)。
  • 术后即刻中位评分(四分位距)注射组为1.6(0至4.0),对照组为3.2(1.3至5.7)。
  • 术后4小时中位评分注射组为1.0(0至3.0),对照组为5.0(2.0至7.0)。
  • 术后8小时中位评分注射组为2.0(0至4.0),对照组为5.0(2.0至6.8)。
  • 术后12小时中位评分注射组为3.5(0至5.0),对照组为5.0(2.0至8.0);术后前8小时麻醉药品消耗量注射组为5.0 mg(1.3至8.0 mg),对照组为9.7 mg(3.9至15.6 mg),注射组显著更低(p = 0.007)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multimodal analgesia inclusive of periarticular injection with a local anesthetic agent has been rapidly assimilated, with demonstrated safety and efficacy, into the care of patients undergoing elective lower-extremity arthroplasty. The present study was performed to evaluate the efficacy and safety of a surgical-site, multimodal drug injection for postoperative pain control following operative management of femoral fractures. METHODS: There were 102 patients undergoing operative intervention (plate fixation, intramedullary device, or arthroplasty) for a broad range of femoral fracture patterns who were prospectively randomized either to receive an intraoperative, surgical-site injection into the superficial and deep tissues containing ropivacaine, epinephrine, and morphine or to receive no injection. Visual analog scale (VAS) scores were recorded at regular intervals as the primary outcome measure. Narcotic consumption and medication-related side effects were also monitored. RESULTS: The injection group demonstrated significantly lower VAS scores (p < 0.05) than the control cohort in the recovery room and at the 4, 8, and 12-hour postoperative time points. The median score (and interquartile range) was 1.6 (0 to 4.0) for the injection group and 3.2 (1.3 to 5.7) for the control group immediately postoperatively, 1.0 (0 to 3.0) for the injection group and 5.0 (2.0 to 7.0) for the control group at 4 hours, 2.0 (0 to 4.0) for the injection group and 5.0 (2.0 to 6.8) for the control group at 8 hours, and 3.5 (0 to 5.0) for the injection group and 5.0 (2.0 to 8.0) for the control group at 12 hours. Additionally, narcotic consumption was significantly lower (p = 0.007) in the injection group (5.0 mg [1.3 to 8.0 mg]) compared with the control group (9.7 mg [3.9 to 15.6 mg]) over the first 8 hours following the surgical procedure. No cardiac or central nervous system toxicity was observed secondary to infiltration of the local anesthetic. CONCLUSIONS: Surgical-site injection with a multimodal analgesic cocktail provides improved pain control and reduces narcotic utilization over the first postoperative day, with no observed adverse effects attributable to the local injection, across a diverse orthopaedic trauma population undergoing operative intervention for femoral fractures. LEVEL OF EVIDENCE: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Koehler D, Marsh JL, Karam M, et al. Efficacy of Surgical-Site, Multimodal Drug Injection Following Operative Management of Femoral Fractures: A Randomized Controlled Trial. J Bone Joint Surg Am. 2017. PMID: 28291185. doi:10.2106/JBJS.16.00733

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。